Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIQ Open-Label Extension for Breakthrough Pain in Children
NCT00236093Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Oct 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of Painkyl in breakthrough pain, sponsored by Cephalon, Inc. Primary endpoint: Adverse Event Data at 4 weeks. Started Oct 2006; status: completed.
02
Drugs
Painkyl
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT00236093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236093.